Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

To predict the public health impact on cervical disease by introducing human papillomavirus (HPV) vaccination in the United Kingdom, we developed a mathematical model that can be used to reflect the impact of vaccination in different countries with existing screening programmes. Its use is discussed in the context of the United Kingdom. The model was calibrated with published data. The impact of vaccination on cervical cancer and deaths, precancerous lesions and screening outcomes were estimated for a vaccinated cohort of 12-year-old girls, among which it is estimated that there would be a reduction of 66% in the prevalence of high-grade precancerous lesions and a 76% reduction in cervical cancer deaths. Estimates for various other measures of the population effects of vaccination are also presented. We concluded that it is feasible to forecast the potential effects of HPV vaccination in the context of an existing national screening programme. Results suggest a sizable reduction in the incidence of cervical cancer and related deaths. Areas for future research include investigation of the beneficial effects of HPV vaccination on infection transmission and epidemic dynamics, as well as HPV-related neoplasms in other sites.

[1]  C. Wheeler,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .

[2]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[3]  Calum MacAulay,et al.  Natural History of Cervical Intraepithelial Neoplasia , 2005, Acta Cytologica.

[4]  T. Rohan,et al.  Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. , 1999, Journal of the National Cancer Institute.

[5]  J. Cuzick,et al.  Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. , 2006, Vaccine.

[6]  N. Kitchin,et al.  Determinants of universal adolescent hepatitis B vaccine uptake , 2004, Archives of Disease in Childhood.

[7]  Lydia P. Howell,et al.  NATURAL HISTORY OF CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[8]  A. Moscicki,et al.  Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. , 2001, JAMA.

[9]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[10]  Daron G Ferris,et al.  Efficacy of a bivalent L 1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial , 2005 .

[11]  Scott B. Cantor,et al.  COLPOSCOPY FOR THE DIAGNOSIS OF SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[12]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[13]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[14]  T. Rohan,et al.  Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. , 2003, Journal of the National Cancer Institute.

[15]  M. Plummer,et al.  Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. , 2003, American journal of epidemiology.

[16]  Milton C Weinstein,et al.  Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.

[17]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[18]  Shalini L Kulasingam,et al.  Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. , 2003, JAMA.

[19]  J. V. van Dijck,et al.  Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996. , 2002, European journal of cancer.

[20]  S. Franceschi,et al.  Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[21]  T. Rohan,et al.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. , 1999, The Journal of infectious diseases.

[22]  J. Cuzick,et al.  Human papillomavirus testing in primary cervical screening , 1995, The Lancet.

[23]  K. Straif,et al.  Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.

[24]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[25]  M K Campbell,et al.  Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. , 2004, Health technology assessment.

[26]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[27]  A. Miller,et al.  Natural history of dysplasia of the uterine cervix. , 1999, Journal of the National Cancer Institute.

[28]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[29]  D. Jenkins,et al.  Withdrawing low risk women from cervical screening programmes: mathematical modelling study. , 1999, BMJ.

[30]  S Gallivan,et al.  Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. , 1994, Journal of clinical pathology.

[31]  Z. Philips,et al.  An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme , 2004, British Journal of Cancer.

[32]  J. Peto,et al.  Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort , 2004, British Journal of Cancer.

[33]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[34]  K. Jørgensen.  [Cervix cancer screening]. , 2008, Ugeskrift for laeger.

[35]  S Gallivan,et al.  Can papilloma virus testing be used to improve cervical cancer screening? , 1996, International journal of cancer.

[36]  P. Kenemans,et al.  Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. , 1998, Obstetrical & gynecological survey.

[37]  L Beardsley,et al.  Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.

[38]  V Beral,et al.  The predicted effect of changes in cervical screening practice in the UK: results from a modelling study , 2004, British Journal of Cancer.

[39]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[40]  J Chilcott,et al.  Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. , 2004, Health technology assessment.

[41]  H. Kitchener,et al.  Psychological response to cervical screening. , 1995, Preventive medicine.

[42]  S. Franceschi,et al.  Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis , 2003, British Journal of Cancer.